Home Print this page Email this page Small font size Default font size Increase font size
Users Online: 1072
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Contacts Login 

    Article Cited by others


Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea

Jain Parveen, Das V. N. R., Ranjan Alok, Chaudhary Rahul, Pandey Krishna

Year : 2013| Volume: 2| Issue : 4 | Page no: 156-161

   This article has been cited by
1 Variables associated with self-reported anxiety and depression symptoms in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy
Dayu Shi,Zongru Li,Yongjie Li,Qian Jiang
Leukemia & Lymphoma. 2020; : 1
[Pubmed]  [Google Scholar] [DOI]
2 Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase
Alauldeen Mudhafar Zubair Alqasim,Ghasaq Mohsin Obaid,Yusra Ghaith Yaseen,Alaa Fadhil Alwan
Leukemia Research Reports. 2019; 11: 46
[Pubmed]  [Google Scholar] [DOI]
3 Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review
Sicília Rezende Oliveira,Luciana Gravito de Azevedo Branco,Amanda Leal Rocha,Denise Vieira Travassos,Gustavo Henrique Romani Magalhães,Felipe Paiva Fonseca,Ricardo Alves Mesquita,Lucas Guimarães Abreu,Tarcília Aparecida da Silva
Clinical Oral Investigations. 2019;
[Pubmed]  [Google Scholar] [DOI]
4 Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study
Lu Yu,Haibo Wang,Darko Milijkovic,Xiaojun Huang,Qian Jiang
BMC Cancer. 2018; 18(1)
[Pubmed]  [Google Scholar] [DOI]
5 Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy
Qian Jiang,Hai-Bo Wang,Lu Yu,Robert Peter Gale
Journal of Cancer Research and Clinical Oncology. 2017;
[Pubmed]  [Google Scholar] [DOI]
6 Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia
Qian Jiang,Haibo Wang,Lu Yu,Robert Peter Gale
Journal of Cancer Research and Clinical Oncology. 2017;
[Pubmed]  [Google Scholar] [DOI]
7 Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression
Afia Muhammad Akram,Zafar Iqbal,Tanveer Akhtar,Ahmed Mukhtar Khalid,Muhammad Farooq Sabar,Mahmood Hussain Qazi,Zeba Aziz,Nadia Sajid,Aamer Aleem,Mahmood Rasool,Muhammad Asif,Saleh Aloraibi,Khaled Aljamaan,Mudassar Iqbal
Cancer Biology & Therapy. 2017; : 00
[Pubmed]  [Google Scholar] [DOI]
8 Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting
Blaise Felix Faye,Nata Dieng,Moussa Seck,Macoura Gadji,Youssou Bamar Gueye,Diariatou Sy,Sokhna Aissatou Toure,Abibatou Sall,Awa Oumar Toure,Tandakha Ndiaye Dieye,Saliou Diop
Annals of Hematology. 2016;
[Pubmed]  [Google Scholar] [DOI]
9 Comprehensive evaluation of adherence to therapy, its associations, and its implications in patients of chronic myeloid leukemia on imatinib
Radhika Unnikrishnan,Surendran Veeraiah,Samson Mani,Rejiv Rajendranath,Swaminathan Rajaraman,Grace Sahaya Vidhubala Elangovan,Venkatraman Radhakrishnan,Trivadi S. Ganesan,Tenali G. Sagar,Prasanth Ganesan
Clinical Lymphoma Myeloma and Leukemia. 2016;
[Pubmed]  [Google Scholar] [DOI]
10 Treatment and Survival in Patients with Chronic Myeloid Leukemia in a Chronic Phase in West Iran
Mehrdad Payandeh,Masoud Sadeghi,Edris Sadeghi
Asian Pacific Journal of Cancer Prevention. 2015; 16(17): 7555
[Pubmed]  [Google Scholar] [DOI]


Read this article